• Incyte is trading 4.4% up at $109.00 today, buoyed by several positive company-specific announcements.
  • Truist Securities raised its price target to $105.00 (from $103.00) in a June 22, 2026 research note, and BMO Capital also upgraded the stock and raised its price target.
  • Further positive catalysts include regulatory approval for Minjuvi® in Japan, positive Phase II results for zilurgisertib leading to FDA Priority Review, and a $246 million non-cash benefit from a CMS settlement over Opzelura.